An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression

Cancer Cell

Volumn 32, Issue 5, 2017, Pages 669-683.e5

  Palazon, Asis ^a   Tyrakis, Petros A ^a,b   Macias, David ^b   Veliça, Pedro ^c   Rundqvist, Helene ^c   Fitzpatrick, Susan ^b   Vojnovic, Nikola ^c   Phan, Anthony T ^d   Loman, Niklas ^e   Hedenfalk, Ingrid ^e   Hatschek, Thomas ^c   Lövrot, John ^c   Foukakis, Theodoros ^c   Goldrath, Ananda W ^d   Bergh, Jonas ^c   Johnson, Randall S ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LUND UNIVERSITY   (Sweden)

Author keywords

angiogenesis; cytotoxic T cells; HIF transcription factors; hypoxia; immunotherapy; VEGF

Indexed keywords

BEVACIZUMAB; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SUNITINIB; TUMOR NECROSIS FACTOR; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN A;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE DELETION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; BREAST TUMOR; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELL CULTURE; DISEASE EXACERBATION; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PROCEDURES; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES, CYTOTOXIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85033695630     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.10.003     Document Type: Article

References (63)

1. Bergh, J., Bondarenko, I.M., Lichinitser, M.R., Liljegren, A., Greil, R., Voytko, N.L., Makhson, A.N., Cortes, J., Lortholary, A., Bischoff, J., et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J. Clin. Oncol. 30 (2012), 921–929.
2. Branco-Price, C., Zhang, N., Schnelle, M., Evans, C., Katschinski, D.M., Liao, D., Ellies, L., Johnson, R.S., Endothelial cell HIF-1alpha and HIF-2alpha differentially regulate metastatic success. Cancer Cell 21 (2012), 52–65.
3. Buck, M.D., O'Sullivan, D., Pearce, E.L., T cell metabolism drives immunity. J. Exp. Med. 212 (2015), 1345–1360.
4. Carmeliet, P., Jain, R.K., Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10 (2011), 417–427.
5. Cham, C.M., Gajewski, T.F., Metabolic mechanisms of tumor resistance to T cell effector function. Immunol. Res. 31 (2005), 107–118.
6. Chang, C.H., Curtis, J.D., Maggi, L.B. Jr., Faubert, B., Villarino, A.V., O'Sullivan, D., Huang, S.C., van der Windt, G.J., Blagih, J., Qiu, J., et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153 (2013), 1239–1251.
7. Claesson-Welsh, L., Welsh, M., VEGFA and tumour angiogenesis. J. Intern. Med. 273 (2013), 114–127.
8. Clever, D., Roychoudhuri, R., Constantinides, M.G., Askenase, M.H., Sukumar, M., Klebanoff, C.A., Eil, R.L., Hickman, H.D., Yu, Z., Pan, J.H., et al. Oxygen sensing by T cells establishes an immunologically tolerant metastatic niche. Cell 166 (2016), 1117–1131.e14.
9. Cramer, T., Yamanishi, Y., Clausen, B.E., Forster, I., Pawlinski, R., Mackman, N., Haase, V.H., Jaenisch, R., Corr, M., Nizet, V., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112 (2003), 645–657.
10. Dang, E.V., Barbi, J., Yang, H.Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.R., et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 146 (2011), 772–784.
11. Davie, S.A., Maglione, J.E., Manner, C.K., Young, D., Cardiff, R.D., MacLeod, C.L., Ellies, L.G., Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res. 16 (2007), 193–201.
12. DeNardo, D.G., Brennan, D.J., Rexhepaj, E., Ruffell, B., Shiao, S.L., Madden, S.F., Gallagher, W.M., Wadhwani, N., Keil, S.D., Junaid, S.A., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1 (2011), 54–67.
13. Detmar, M., Brown, L.F., Schon, M.P., Elicker, B.M., Velasco, P., Richard, L., Fukumura, D., Monsky, W., Claffey, K.P., Jain, R.K., Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. Dermatol. 111 (1998), 1–6.
14. Doedens, A.L., Phan, A.T., Stradner, M.H., Fujimoto, J.K., Nguyen, J.V., Yang, E., Johnson, R.S., Goldrath, A.W., Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat. Immunol. 14 (2013), 1173–1182.
15. Facciabene, A., Peng, X., Hagemann, I.S., Balint, K., Barchetti, A., Wang, L.P., Gimotty, P.A., Gilks, C.B., Lal, P., Zhang, L., Coukos, G., Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475 (2011), 226–230.
16. + T cells. J. Exp. Med. 209 (2012), 2441–2453.
17. Foukakis, T., Lovrot, J., Sandqvist, P., Xie, H., Lindstrom, L.S., Giorgetti, C., Jacobsson, H., Hedayati, E., Bergh, J., Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer. Mol. Oncol. 9 (2015), 1384–1391.
18. Freeman, M.R., Schneck, F.X., Gagnon, M.L., Corless, C., Soker, S., Niknejad, K., Peoples, G.E., Klagsbrun, M., Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res. 55 (1995), 4140–4145.
19. Galon, J., Angell, H.K., Bedognetti, D., Marincola, F.M., The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39 (2013), 11–26.
20. Gerber, H.P., Malik, A.K., Solar, G.P., Sherman, D., Liang, X.H., Meng, G., Hong, K., Marsters, J.C., Ferrara, N., VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417 (2002), 954–958.
21. Goel, S., Wong, A.H., Jain, R.K., Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb. Perspect. Med., 2, 2012, a006486.
22. Gros, A., Robbins, P.F., Yao, X., Li, Y.F., Turcotte, S., Tran, E., Wunderlich, J.R., Mixon, A., Farid, S., Dudley, M.E., et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124 (2014), 2246–2259.
23. Gruber, M., Hu, C.J., Johnson, R.S., Brown, E.J., Keith, B., Simon, M.C., Acute postnatal ablation of Hif-2alpha results in anemia. Proc. Natl. Acad. Sci. USA 104 (2007), 2301–2306.
24. Guy, C.T., Cardiff, R.D., Muller, W.J., Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12 (1992), 954–961.
25. Hansen, W., Hutzler, M., Abel, S., Alter, C., Stockmann, C., Kliche, S., Albert, J., Sparwasser, T., Sakaguchi, S., Westendorf, A.M., et al. Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J. Exp. Med. 209 (2012), 2001–2016.
26. Hodi, F.S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M.B., Ibrahim, N., et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2 (2014), 632–642.
27. Hogquist, K.A., Jameson, S.C., Heath, W.R., Howard, J.L., Bevan, M.J., Carbone, F.R., T cell receptor antagonist peptides induce positive selection. Cell 76 (1994), 17–27.
28. Jantsch, J., Chakravortty, D., Turza, N., Prechtel, A.T., Buchholz, B., Gerlach, R.G., Volke, M., Glasner, J., Warnecke, C., Wiesener, M.S., et al. Hypoxia and hypoxia-inducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function. J. Immunol. 180 (2008), 4697–4705.
29. June, C.H., Riddell, S.R., Schumacher, T.N., Adoptive cellular therapy: a race to the finish line. Sci. Transl. Med., 7, 2015, 280ps287.
30. Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M., Old, L.J., Schreiber, R.D., Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95 (1998), 7556–7561.
31. Kim, I., Moon, S.O., Park, S.K., Chae, S.W., Koh, G.Y., Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ. Res. 89 (2001), 477–479.
32. Kim, J.W., Evans, C., Weidemann, A., Takeda, N., Lee, Y.S., Stockmann, C., Branco-Price, C., Brandberg, F., Leone, G., Ostrowski, M.C., Johnson, R.S., Loss of fibroblast HIF-1alpha accelerates tumorigenesis. Cancer Res. 72 (2012), 3187–3195.
33. Kim, J.W., Tchernyshyov, I., Semenza, G.L., Dang, C.V., HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3 (2006), 177–185.
34. Lee, J.H., Elly, C., Park, Y., Liu, Y.C., E3 Ubiquitin ligase VHL regulates hypoxia-inducible factor-1alpha to maintain regulatory T cell stability and suppressive capacity. Immunity 42 (2015), 1062–1074.
35. Lin, E.Y., Jones, J.G., Li, P., Zhu, L., Whitney, K.D., Muller, W.J., Pollard, J.W., Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163 (2003), 2113–2126.
36. Lin, E.Y., Li, J.F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D.A., Qian, H., Xue, X.N., Pollard, J.W., Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66 (2006), 11238–11246.
37. Linderholm, B.K., Lindh, B., Beckman, L., Erlanson, M., Edin, K., Travelin, B., Bergh, J., Grankvist, K., Henriksson, R., Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin. Breast Cancer 4 (2003), 340–347.
38. McNamee, E.N., Korns Johnson, D., Homann, D., Clambey, E.T., Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function. Immunol. Res. 55 (2013), 58–70.
39. Melder, R.J., Koenig, G.C., Witwer, B.P., Safabakhsh, N., Munn, L.L., Jain, R.K., During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat. Med. 2 (1996), 992–997.
40. Miller, L.D., Smeds, J., George, J., Vega, V.B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., Liu, E.T., Bergh, J., An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 102 (2005), 13550–13555.
41. Motz, G.T., Santoro, S.P., Wang, L.P., Garrabrant, T., Lastra, R.R., Hagemann, I.S., Lal, P., Feldman, M.D., Benencia, F., Coukos, G., Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20 (2014), 607–615.
42. Nakamura, H., Makino, Y., Okamoto, K., Poellinger, L., Ohnuma, K., Morimoto, C., Tanaka, H., TCR engagement increases hypoxia-inducible factor-1 alpha protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells. J. Immunol. 174 (2005), 7592–7599.
43. Ohm, J.E., Gabrilovich, D.I., Sempowski, G.D., Kisseleva, E., Parman, K.S., Nadaf, S., Carbone, D.P., VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101 (2003), 4878–4886.
44. Palazon, A., Goldrath, A.W., Nizet, V., Johnson, R.S., HIF transcription factors, inflammation, and immunity. Immunity 41 (2014), 518–528.
45. Papandreou, I., Cairns, R.A., Fontana, L., Lim, A.L., Denko, N.C., HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3 (2006), 187–197.
46. Pearce, E.L., Poffenberger, M.C., Chang, C.H., Jones, R.G., Fueling immunity: insights into metabolism and lymphocyte function. Science, 342, 2013, 1242454.
47. Peng, W., Chen, J.Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M.T., Xu, C., McKenzie, J.A., Zhang, C., Liang, X., et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6 (2016), 202–216.
48. Ramello, M.C., Tosello Boari, J., Canale, F.P., Mena, H.A., Negrotto, S., Gastman, B., Gruppi, A., Acosta Rodriguez, E.V., Montes, C.L., Tumor-induced senescent T cells promote the secretion of pro-inflammatory cytokines and angiogenic factors by human monocytes/macrophages through a mechanism that involves Tim-3 and CD40L. Cell Death Dis., 5, 2014, e1507.
49. Ryan, H.E., Poloni, M., McNulty, W., Elson, D., Gassmann, M., Arbeit, J.M., Johnson, R.S., Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60 (2000), 4010–4015.
50. Seagroves, T.N., Ryan, H.E., Lu, H., Wouters, B.G., Knapp, M., Thibault, P., Laderoute, K., Johnson, R.S., Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol. Cell. Biol. 21 (2001), 3436–3444.
51. Semenza, G.L., Hypoxia-inducible factors in physiology and medicine. Cell 148 (2012), 399–408.
52. Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J., Schreiber, R.D., IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001), 1107–1111.
53. Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
54. Shi, L.Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D.R., Chi, H., HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208 (2011), 1367–1376.
55. Shojaei, F., Zhong, C., Wu, X., Yu, L., Ferrara, N., Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol. 18 (2008), 372–378.
56. Stockmann, C., Doedens, A., Weidemann, A., Zhang, N., Takeda, N., Greenberg, J.I., Cheresh, D.A., Johnson, R.S., Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456 (2008), 814–818.
57. Takeda, N., O'Dea, E.L., Doedens, A., Kim, J.W., Weidemann, A., Stockmann, C., Asagiri, M., Simon, M.C., Hoffmann, A., Johnson, R.S., Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis. Genes Dev. 24 (2010), 491–501.
58. Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A.F., Tartour, E., Taieb, J., VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 73 (2013), 539–549.
59. Vaupel, P., Kallinowski, F., Okunieff, P., Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49 (1989), 6449–6465.
60. Walmsley, S.R., Print, C., Farahi, N., Peyssonnaux, C., Johnson, R.S., Cramer, T., Sobolewski, A., Condliffe, A.M., Cowburn, A.S., Johnson, N., Chilvers, E.R., Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J. Exp. Med. 201 (2005), 105–115.
61. Wu, X., Giobbie-Hurder, A., Liao, X., Lawrence, D., McDermott, D., Zhou, J., Rodig, S., Hodi, F.S., VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma. Cancer Immunol. Res. 4 (2016), 858–868.
62. Zhang, D.J., Wang, Q., Wei, J., Baimukanova, G., Buchholz, F., Stewart, A.F., Mao, X., Killeen, N., Selective expression of the Cre recombinase in late-stage thymocytes using the distal promoter of the Lck gene. J. Immunol. 174 (2005), 6725–6731.
63. Zhang, N., Bevan, M.J., Dicer controls CD8+ T-cell activation, migration, and survival. Proc. Natl. Acad. Sci. USA 107 (2010), 21629–21634.